Evofem Biosciences, Inc. (EVFM) Financial Statements (2025 and earlier)

Company Profile

Business Address 12400 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
ASSETS
Current Assets
Restricted cash and investments722692689580410600
Receivables5,3934,6174,3065,7386,3225,198
Inventory, net of allowances, customer advances and progress billings1,4631,0601,3061,6972,5263,674
Inventory1,4631,0601,3061,6972,5263,674
Prepaid expense774832609   
Deposits current assets202     
Other undisclosed current assets2313131,1952,2472,544
Total current assets:8,5777,2146,9239,21011,50512,016
Noncurrent Assets
Operating lease, right-of-use asset12711459106151195
Property, plant and equipment1,1811,1871,2001,2031,6311,668
Intangible assets, net (including goodwill)14,021     
Intangible assets, net (excluding goodwill)14,021     
Other noncurrent assets3636353535195
Total noncurrent assets:15,3651,3371,2941,3441,8172,058
TOTAL ASSETS:23,9428,5518,21710,55413,32214,074
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities21,98820,78520,86921,24721,29921,367
Accounts payable16,86416,03316,29417,02016,19917,151
Accrued liabilities5,1244,7524,5754,2275,1004,216
Deferred revenue 4,5003,6003,200   
Debt268397 14,73113,11015,600
Derivative instruments and hedges, liabilities1629424,3101,926  
Other liabilities 3,7763,3913,3163,5323,625
Other undisclosed current liabilities49,36843,67842,46931,24329,92729,124
Total current liabilities:76,28673,17874,23972,46367,86869,716
Noncurrent Liabilities
Liabilities, other than long-term debt101481322
Operating lease, liability101481322
Other undisclosed noncurrent liabilities13,775     
Total noncurrent liabilities:13,7851481322
Total liabilities:90,07173,17974,24372,47167,88169,738
Temporary equity, including noncontrolling interest4,7594,6874,6404,5931,800 
Equity
Equity, attributable to parent(70,888)(69,315)(70,666)(66,510)(56,359)(55,664)
Common stock10852  
Additional paid in capital825,430823,709823,409823,036828,552820,587
Accumulated other comprehensive income (loss)(1,707)(781)(525)(849)(287)73,355
Accumulated deficit(894,621)(892,251)(893,555)(888,699)(884,624)(949,606)
Total equity:(70,888)(69,315)(70,666)(66,510)(56,359)(55,664)
TOTAL LIABILITIES AND EQUITY:23,9428,5518,21710,55413,32214,074

Income Statement (P&L) ($ in thousands)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
Revenues4,4964,1603,6034,8395,1122,458
Loss on disposition of assets for financial service operations  (25)(3,275)   
Cost of revenue
(Cost of Product and Service Sold)
(869)(769)(684)(954)(1,889)(2,293)
Gross profit:3,6273,3912,9193,8853,223165
Operating expenses(6,067)(4,780)(5,763)(7,265)(6,775)(7,501)
Operating loss:(2,440)(1,389)(2,844)(3,380)(3,552)(7,336)
Nonoperating income (expense)672,748(1,965)1,26669,568(1,219)
Other nonoperating expense(562)(558)(616)(587)(596)(1,127)
Interest and debt expense(556)(546)(564)(568)(567)(567)
Income (loss) from continuing operations before equity method investments, income taxes:(2,929)813(5,373)(2,682)65,449(9,122)
Other undisclosed income from continuing operations before income taxes556546564568567567
Income (loss) from continuing operations before income taxes:(2,373)1,359(4,809)(2,114)66,016(8,555)
Income tax expense (benefit) 8(8)  (11)(3)
Net income (loss) attributable to parent:(2,365)1,351(4,809)(2,114)66,005(8,558)
Other undisclosed net loss available to common stockholders, basic(5)(47)(47)(2,984)  
Net income (loss) available to common stockholders, basic:(2,370)1,304(4,856)(5,098)66,005(8,558)
Interest on convertible debt    368361 
Other undisclosed net income (loss) available to common stockholders, diluted  (3,300) (3,755)4,904 
Net income (loss) available to common stockholders, diluted:(2,370)(1,996)(4,856)(8,485)71,270(8,558)

Comprehensive Income ($ in thousands)

12/31/2024
Q4
9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
Net income (loss):(2,365)1,351(4,809)(2,114)66,005(8,558)
Comprehensive income (loss):(2,365)1,351(4,809)(2,114)66,005(8,558)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(926)(256)324(559)(73,642)8,368
Comprehensive income (loss), net of tax, attributable to parent:(3,291)1,095(4,485)(2,673)(7,637)(190)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: